<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TRANDATE- labetalol hydrochloride tablet </strong><br>Prometheus Laboratories Inc.<br></p></div>
<h1>TRANDATE<span class="Sup">®</span><br>(labetalol hydrochloride) <br>Tablets
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION
</h1>
<p class="First">TRANDATE Tablets are adrenergic receptor blocking agents that have both selective alpha<span class="Sub">1</span>-adrenergic and nonselective beta-adrenergic receptor blocking actions in a single substance.
</p>
<p> Labetalol hydrochloride (HCl) is a racemate chemically designated as 2-hydroxy-5-[1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl]benzamide monohydrochloride, and it has the following structure:
</p>
<div class="Figure">
<a name="f01"></a><img alt="Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a4195473-51a9-40f1-8678-1478ebca2d84&amp;name=tra08-0004-01.jpg">
</div>
<p> Labetalol HCl has the empirical formula C<span class="Sub">19</span>H<span class="Sub">24</span>N<span class="Sub">2</span>O<span class="Sub">3</span>•HCl and a molecular weight of 364.9. It has two asymmetric centers and therefore exists as a molecular complex of two diastereoisomeric pairs. Dilevalol, the R,R´ stereoisomer, makes up 25% of racemic labetalol.
</p>
<p> Labetalol HCl is a white or off-white crystalline powder, soluble in water.
</p>
<p> TRANDATE Tablets contain 100, 200, or 300 mg of labetalol HCl and are taken orally. The tablets also contain the inactive ingredients corn starch, FD&amp;C Yellow No. 6 (100- and 300-mg tablets only), hydroxypropyl methylcellulose, lactose, magnesium stearate, pregelatinized corn starch, sodium benzoate (200-mg tablet only), talc (100-mg tablet only), and titanium dioxide.
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY
</h1>
<p class="First">Labetalol HCl combines both selective, competitive, alpha<span class="Sub">1</span>-adrenergic blocking and nonselective, competitive, beta-adrenergic blocking activity in a single substance. In man, the ratios of alpha- to beta-blockade have been estimated to be approximately 1:3 and 1:7 following oral and intravenous (IV) administration, respectively. Beta<span class="Sub">2</span>-agonist activity has been demonstrated in animals with minimal beta<span class="Sub">1</span>-agonist (ISA) activity detected. In animals, at doses greater than those required for alpha- or beta-adrenergic blockade, a membrane stabilizing effect has been demonstrated. 
</p>
<div class="Section" data-sectionCode="43681-6">
<a name="s3"></a><a name="section-2.1"></a><p></p>
<p class="First"><span class="Bold">Pharmacodynamics:</span> The capacity of labetalol HCl to block alpha receptors in man has been demonstrated by attenuation of the pressor effect of phenylephrine and by a significant reduction of the pressor response caused by immersing the hand in ice-<span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> water ("<span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>-pressor test"). Labetalol HCl's beta<span class="Sub">1</span>-receptor blockade in man was demonstrated by a small decrease in the resting heart rate, attenuation of <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> produced by isoproterenol or exercise, and by attenuation of the <span class="product-label-link" type="condition" conceptid="444070" conceptname="Tachycardia">reflex tachycardia</span> to the <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> produced by amyl nitrite. Beta<span class="Sub">2</span>-receptor blockade was demonstrated by inhibition of the isoproterenol-induced <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in diastolic blood pressure. Both the alpha- and beta-blocking actions of orally administered labetalol HCl contribute to a decrease in blood pressure in hypertensive patients. Labetalol HCl consistently, in dose-related fashion, blunted increases in exercise-induced blood pressure and heart rate, and in their double product. The pulmonary circulation during exercise was not affected by labetalol HCl dosing.
</p>
<p> Single oral doses of labetalol HCl administered to patients with <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> had no significant effect on sinus rate, intraventricular conduction, or QRS duration. The atrioventricular (A-V) conduction time was modestly prolonged in two of seven patients. In another study, IV labetalol HCl slightly prolonged A-V nodal conduction time and atrial effective refractory period with only small changes in heart rate. The effects on A-V nodal refractoriness were inconsistent.
</p>
<p> Labetalol HCl produces dose-related <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> in blood pressure without <span class="product-label-link" type="condition" conceptid="444070" conceptname="Tachycardia">reflex tachycardia</span> and without significant reduction in heart rate, presumably through a mixture of its alpha- and beta-blocking effects. Hemodynamic effects are variable, with small, nonsignificant changes in <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> seen in some studies but not others, and small decreases in total peripheral resistance. Elevated plasma renins are reduced.
</p>
<p> Doses of labetalol HCl that controlled <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> did not affect renal function in mildly to severely hypertensive patients with normal renal function.
</p>
<p> Due to the alpha<span class="Sub">1</span>-receptor blocking activity of labetalol HCl, blood pressure is lowered more in the standing than in the supine position, and symptoms of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span> (2%), including rare instances of <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, can occur. Following oral administration, when <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span> has occurred, it has been transient and is uncommon when the recommended starting dose and titration increments are closely followed (see <a href="#s34">DOSAGE AND ADMINISTRATION</a>). Symptomatic <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span> is most likely to occur 2 to 4 hours after a dose, especially following the use of large initial doses or upon large changes in dose.
</p>
<p> The peak effects of single oral doses of labetalol HCl occur within 2 to 4 hours. The duration of effect depends upon dose, lasting at least 8 hours following single oral doses of 100 mg and more than 12 hours following single oral doses of 300 mg. The maximum, steady-state blood pressure response upon oral, twice-a-day dosing occurs within 24 to 72 hours.
</p>
<p> The antihypertensive effect of labetalol has a linear correlation with the logarithm of labetalol plasma concentration, and there is also a linear correlation between the reduction in exercise-induced <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> occurring at 2 hours after oral administration of labetalol HCl and the logarithm of the plasma concentration.
</p>
<p> About 70% of the maximum beta-blocking effect is present for 5 hours after the administration of a single oral dose of 400 mg with suggestion that about 40% remains at 8 hours.
</p>
<p> The antianginal efficacy of labetalol HCl has not been studied. In 37 patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>, labetalol HCl did not increase the incidence or severity of <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina attacks</span>.
</p>
<p> Exacerbation of angina and, in some cases, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and ventricular <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">dysrhythmias</span> have been reported after abrupt discontinuation of therapy with beta-adrenergic blocking agents in patients with <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>. Abrupt withdrawal of these agents in patients without <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> has resulted in transient symptoms, including <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremulousness</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>. Several mechanisms have been proposed to explain these phenomena, among them increased sensitivity to catecholamines because of increased numbers of beta receptors.
</p>
<p> Although beta-adrenergic receptor blockade is useful in the treatment of angina and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, there are also situations in which sympathetic stimulation is vital. For example, in patients with severely damaged hearts, adequate ventricular function may depend on sympathetic drive. Beta-adrenergic blockade may worsen A-V block by preventing the necessary facilitating effects of sympathetic activity on conduction. Beta<span class="Sub">2</span>-adrenergic blockade results in passive bronchial constriction by interfering with endogenous adrenergic bronchodilator activity in patients subject to <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, and it may also interfere with exogenous bronchodilators in such patients.
</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s4"></a><a name="section-2.2"></a><p></p>
<p class="First"><span class="Bold">Pharmacokinetics and Metabolism:</span> Labetalol HCl is completely absorbed from the gastrointestinal tract with peak plasma levels occurring 1 to 2 hours after oral administration. The relative bioavailability of labetalol HCl tablets compared to an oral solution is 100%. The absolute bioavailability (fraction of drug reaching systemic circulation) of labetalol when compared to an IV infusion is 25%; this is due to extensive "first-pass" metabolism. Despite "first-pass" metabolism, there is a linear relationship between oral doses of 100 to 3,000 mg and peak plasma levels. The absolute bioavailability of labetalol is increased when administered with food.
</p>
<p> The plasma half-life of labetalol following oral administration is about 6 to 8 hours. Steady-state plasma levels of labetalol during repetitive dosing are reached by about the third day of dosing. In patients with decreased hepatic or renal function, the elimination half-life of labetalol is not altered; however, the relative bioavailability in hepatically impaired patients is increased due to decreased "first-pass" metabolism.
</p>
<p> The metabolism of labetalol is mainly through conjugation to glucuronide metabolites. These metabolites are present in plasma and are excreted in the urine and, via the bile, into the feces. Approximately 55% to 60% of a dose appears in the urine as conjugates or unchanged labetalol within the first 24 hours of dosing.
</p>
<p> Labetalol has been shown to cross the placental barrier in humans. Only negligible amounts of the drug crossed the blood-brain barrier in animal studies. Labetalol is approximately 50% protein bound. Neither hemodialysis nor peritoneal dialysis removes a significant amount of labetalol HCl from the general circulation (&lt;1%).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5"></a><a name="section-2.3"></a><p></p>
<p class="First"><span class="Bold Italics">Elderly Patients:</span> Some pharmacokinetic studies indicate that the elimination of labetalol is reduced in elderly patients. Therefore, although elderly patients may initiate therapy at the currently recommended dosage of 100 mg b.i.d., elderly patients will generally require lower maintenance dosages than nonelderly patients.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s6"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE
</h1>
<p class="First">TRANDATE Tablets are indicated in the management of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. TRANDATE Tablets may be used alone or in combination with other antihypertensive agents, especially thiazide and loop diuretics.
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s7"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS
</h1>
<p class="First">TRANDATE Tablets are contraindicated in bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, overt <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, greater-than-first-degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>, <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">cardiogenic shock</span>, severe <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, other conditions associated with severe and prolonged <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and in patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any component of the product (see <a href="#s8">WARNINGS</a>).
</p>
<p> Beta-blockers, even those with apparent cardioselectivity, should not be used in patients with a history of obstructive airway disease, including <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.
</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s8"></a><a name="section-5"></a><p></p>
<h1>WARNINGS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s9"></a><a name="section-5.1"></a><p></p>
<p class="First"><span class="Bold">Hepatic Injury:</span> Severe <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">hepatocellular injury</span>, confirmed by rechallenge in at least one case, occurs rarely with labetalol therapy. The hepatic injury is usually reversible, but <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have been reported. Injury has occurred after both short- and long-term treatment and may be slowly progressive despite minimal symptomatology. Similar hepatic events have been reported with a related research compound, dilevalol HCl, including two <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>. Dilevalol HCl is one of the four isomers of labetalol HCl. Thus, for patients taking labetalol, periodic determination of suitable hepatic laboratory tests would be appropriate. Appropriate laboratory testing should be done at the first symptom/sign of liver dysfunction (e.g., <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, dark urine, persistent <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, right upper quadrant <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, or unexplained "flu-like" symptoms). If the patient has laboratory evidence of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, labetalol should be stopped and not restarted.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-5.2"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span>:</span> Sympathetic stimulation is a vital component supporting circulatory function in <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. Beta-blockade carries a potential hazard of further depressing myocardial contractility and precipitating more severe failure. Although beta-blockers should be avoided in overt <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, if necessary, labetalol HCl can be used with caution in patients with a history of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> who are well compensated. <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span> has been observed in patients receiving labetalol HCl. Labetalol HCl does not abolish the inotropic action of digitalis on heart muscle.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-5.3"></a><p></p>
<p class="First"><span class="Bold">In Patients Without a History of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span></span>: In patients with latent <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac insufficiency</span>, continued <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>. At the first sign or symptom of impending <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, patients should be fully digitalized and/or be given a diuretic, and the response should be observed closely. If <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> continues despite adequate digitalization and diuretic, therapy with TRANDATE Tablets should be withdrawn (gradually, if possible).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12"></a><a name="section-5.4"></a><p></p>
<p class="First"><span class="Bold">Exacerbation of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Ischemic Heart Disease</span> Following Abrupt Withdrawal:</span> <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">Angina pectoris</span> has not been reported upon labetalol HCl discontinuation. However, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to catecholamines has been observed in patients withdrawn from beta-blocker therapy; exacerbation of angina and, in some cases, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> have occurred after <span class="Italics">abrupt</span> discontinuation of such therapy. When discontinuing chronically administered TRANDATE Tablets, particularly in patients with <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span>, the dosage should be gradually reduced over a period of 1 to 2 weeks and the patient should be carefully monitored. If angina markedly worsens or acute coronary insufficiency develops, therapy with TRANDATE Tablets should be reinstituted promptly, at least temporarily, and other measures appropriate for the management of <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span> should be taken. Patients should be warned against interruption or discontinuation of therapy without the physician's advice. Because <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> is common and may be unrecognized, it may be prudent not to discontinue therapy with TRANDATE Tablets abruptly in patients being treated for <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.
</p>
<p><span class="Bold">Nonallergic <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span> (e.g., <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">Chronic Bronchitis</span> and <span class="product-label-link" type="condition" conceptid="4169883" conceptname="Emphysema">Emphysema</span>): Patients with bronchospastic disease should, in general, not receive beta-blockers.</span> TRANDATE Tablets may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. It is prudent, if TRANDATE Tablets are used, to use the smallest effective dose, so that inhibition of endogenous or exogenous beta-agonists is minimized.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s13"></a><a name="section-5.5"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">Pheochromocytoma</span>:</span> Labetalol HCl has been shown to be effective in lowering blood pressure and relieving symptoms in patients with <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span>. However, paradoxical hypertensive responses have been reported in a few patients with this tumor; therefore, use caution when administering labetalol HCl to patients with <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s14"></a><a name="section-5.6"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus and <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span>:</span> Beta-adrenergic blockade may prevent the appearance of premonitory signs and symptoms (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>) of acute <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. This is especially important with labile diabetics. Beta-blockade also reduces the release of insulin in response to <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>; it may therefore be necessary to adjust the dose of antidiabetic drugs.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s15"></a><a name="section-5.7"></a><p></p>
<p class="First"><span class="Bold">Major Surgery:</span></p>
<p>
									Do not routinely withdraw chronic beta blocker therapy prior to surgery. The effect of labetalol's alpha adrenergic activity has not been evaluated in this setting.
</p>
<p> A synergism between labetalol HCl and halothane anesthesia has been shown (see <a href="#s22">PRECAUTIONS: Drug Interactions</a>).
</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s16"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="s17"></a><a name="section-6.1"></a><p></p>
<h2>General
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s18"></a><a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Bold Italics">Impaired Hepatic Function:</span> TRANDATE Tablets should be used with caution in patients with impaired hepatic function since metabolism of the drug may be diminished.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e6"></a><a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="436397" conceptname="Intraoperative floppy iris syndrome">Intraoperative Floppy Iris Syndrome</span> (IFIS)</span> has been observed during <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery in some patients treated with alpha-1 blockers (labetalol is an alpha/beta blocker).  This variant of small pupil syndrome is characterized by the combination of a flaccid iris that billows in response to intraoperative irrigation currents, progressive intraoperative <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span> despite preoperative dilation with standard mydriatic drugs, and potential prolapse of the iris toward the phacoemulsification incisions.  The patient's ophthalmologist should be prepared for possible modifications to the surgical technique, such as the utilization of iris hooks, iris dilator rings, or viscoelastic substances.  There does not appear to be a benefit of stopping alpha-1 blocker therapy prior to <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s19"></a><a name="section-6.1.3"></a><p></p>
<p class="First"><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">Jaundice</span> or Hepatic Dysfunction:</span> (see <a href="#s8">WARNINGS</a>).
</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s20"></a><a name="section-6.2"></a><p></p>
<p class="First"><span class="Bold">Information for Patients:</span> As with all drugs with beta-blocking activity, certain advice to patients being treated with labetalol HCl is warranted. This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects. While no incident of the abrupt withdrawal phenomenon (exacerbation of <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>) has been reported with labetalol HCl, dosing with TRANDATE Tablets should not be interrupted or discontinued without a physician's advice. Patients being treated with TRANDATE Tablets should consult a physician at any signs or symptoms of impending <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> or hepatic dysfunction (see <a href="#s8">WARNINGS</a>). Also, transient scalp <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> may occur, usually when treatment with TRANDATE Tablets is initiated (see <a href="#s32">ADVERSE REACTIONS</a>).
</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="s21"></a><a name="section-6.3"></a><p></p>
<p class="First"><span class="Bold">Laboratory Tests:</span> As with any new drug given over <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span>, laboratory parameters should be observed over regular intervals. In patients with concomitant illnesses, such as <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, appropriate tests should be done to monitor these conditions.
</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s22"></a><a name="section-6.4"></a><p></p>
<p class="First"><span class="Bold">Drug Interactions:</span> In one survey, 2.3% of patients taking labetalol HCl in combination with tricyclic antidepressants experienced <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, as compared to 0.7% reported to occur with labetalol HCl alone. The contribution of each of the treatments to this adverse reaction is unknown, but the possibility of a drug interaction cannot be excluded.
</p>
<p> Drugs possessing beta-blocking properties can blunt the bronchodilator effect of beta-receptor agonist drugs in patients with <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>; therefore, doses greater than the normal antiasthmatic dose of beta-agonist bronchodilator drugs may be required.
</p>
<p> Cimetidine has been shown to increase the bioavailability of labetalol HCl. Since this could be explained either by enhanced absorption or by an alteration of hepatic metabolism of labetalol HCl, special care should be used in establishing the dose required for blood pressure control in such patients.
</p>
<p> Synergism has been shown between halothane anesthesia and intravenously administered labetalol HCl. During controlled hypotensive anesthesia using labetalol HCl in association with halothane, high concentrations (3% or above) of halothane should not be used because the degree of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> will be increased and because of the possibility of a large reduction in <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> and an increase in central venous pressure. The anesthesiologist should be informed when a patient is receiving labetalol HCl.
</p>
<p> Labetalol HCl blunts the <span class="product-label-link" type="condition" conceptid="444070" conceptname="Tachycardia">reflex tachycardia</span> produced by nitroglycerin without preventing its hypotensive effect. If labetalol HCl is used with nitroglycerin in patients with <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, additional antihypertensive effects may occur.
</p>
<p> Care should be taken if labetalol is used concomitantly with calcium antagonists of the verapamil type.
</p>
<p>Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s23"></a><a name="section-6.4.1"></a><p></p>
<p class="First"><span class="Bold Italics">Risk of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reaction</span>:</span> While taking beta-blockers, patients with a history of severe <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span> to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="s24"></a><a name="section-6.5"></a><p></p>
<p class="First"><span class="Bold">Drug/Laboratory Test Interactions:</span> The presence of labetalol metabolites in the urine may result in falsely elevated levels of urinary catecholamines, metanephrine, normetanephrine, and vanillylmandelic acid when measured by fluorimetric or photometric methods. In screening patients suspected of having a <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span> and being treated with labetalol HCl, a specific method, such as a high performance liquid chromatographic assay with solid phase extraction (e.g., <span class="Italics">J Chromatogr</span> 385:241,1987) should be employed in determining levels of catecholamines.
</p>
<p> Labetalol HCl has also been reported to produce a false-positive test for amphetamine when screening urine for the presence of drugs using the commercially available assay methods TOXI-LAB<span class="Sup">®</span> A (thin-layer chromatographic assay) and EMIT-d.a.u.<span class="Sup">®</span> (radioenzymatic assay). When patients being treated with labetalol have a positive urine test for amphetamine using these techniques, confirmation should be made by using more specific methods, such as a gas chromatographic-<span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> spectrometer technique.
</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s25"></a><a name="section-6.6"></a><p></p>
<p class="First"><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility:</span> Long-term oral dosing studies with labetalol HCl for 18 months in mice and for 2 years in rats showed no evidence of carcinogenesis. Studies with labetalol HCl using dominant lethal assays in rats and mice and exposing microorganisms according to modified Ames tests showed no evidence of mutagenesis.
</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s26"></a><a name="section-6.7"></a><p></p>
<p class="First"><span class="Bold">Pregnancy:</span><span class="Bold Italics">Teratogenic Effects: Pregnancy Category C:</span> Teratogenic studies were performed with labetalol in rats and rabbits at oral doses up to approximately six and four times the maximum recommended human dose (MRHD), respectively. No reproducible evidence of <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span> was observed. Increased fetal resorptions were seen in both species at doses approximating the MRHD. A teratology study performed with labetalol in rabbits at IV doses up to 1.7 times the MRHD revealed no evidence of drug-related harm to the fetus. There are no adequate and well-controlled studies in pregnant women. Labetalol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
</p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="s27"></a><a name="section-6.8"></a><p></p>
<p class="First"><span class="Bold Italics">Nonteratogenic Effects:</span> <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, and <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> have been reported in infants of mothers who were treated with labetalol HCl for <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> during pregnancy. Oral administration of labetalol to rats during late gestation through weaning at doses of two to four times the MRHD caused a decrease in neonatal survival.
</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="s28"></a><a name="section-6.9"></a><p></p>
<p class="First"><span class="Bold">Labor and Delivery:</span> Labetalol HCl given to pregnant women with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> did not appear to affect the usual course of labor and delivery.
</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s29"></a><a name="section-6.10"></a><p></p>
<p class="First"><span class="Bold">Nursing Mothers:</span> Small amounts of labetalol (approximately 0.004% of the maternal dose) are excreted in human milk. Caution should be exercised when TRANDATE Tablets are administered to a nursing woman.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s30"></a><a name="section-6.11"></a><p></p>
<p class="First"><span class="Bold">Pediatric Use:</span> Safety and effectiveness in pediatric patients have not been established.
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s31"></a><a name="section-6.12"></a><p></p>
<p class="First"><span class="Bold">Elderly Patients:</span> As in the general population, some elderly patients (60 years of age and older) have experienced <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span> during treatment with labetalol. Because elderly patients are generally more likely than younger patients to experience orthostatic symptoms, they should be cautioned about the possibility of such side effects during treatment with labetalol.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s32"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS
</h1>
<p class="First">Most adverse effects are mild and transient and occur early in the course of treatment. In controlled clinical trials of 3 to 4 months' duration, discontinuation of TRANDATE Tablets due to one or more adverse effects was required in 7% of all patients. In these same trials, other agents with solely beta-blocking activity used in the control groups led to discontinuation in 8% to 10% of patients, and a centrally acting alpha-agonist led to discontinuation in 30% of patients.
</p>
<p> The incidence rates of adverse reactions listed in the following table were derived from multicenter, controlled clinical trials comparing labetalol HCl, placebo, metoprolol, and propranolol over treatment periods of 3 and 4 months. Where the frequency of adverse effects for labetalol HCl and placebo is similar, causal relationship is uncertain. The rates are based on adverse reactions considered probably drug related by the investigator. If all reports are considered, the rates are somewhat higher (e.g., <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, 20%; <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, 14%; <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, 11%), but the overall conclusions are unchanged.
</p>
<table width="100%">
<col align="left" width="28.080%">
<col align="left" width="19.300%">
<col align="left" width="17.540%">
<col align="left" width="17.540%">
<col align="left" width="17.540%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="center" valign="top"></td>
<td class="Toprule" align="center" valign="top">Labetalol HCI
</td>
<td class="Toprule" align="center" valign="top">Placebo
</td>
<td class="Toprule" align="center" valign="top">Propranolol
</td>
<td class="Toprule" align="center" valign="top">Metoprolol
</td>
</tr>
<tr>
<td align="center" valign="top"></td>
<td align="center" valign="top">(n = 227)
</td>
<td align="center" valign="top">(n = 98)
</td>
<td align="center" valign="top">(n = 84)
</td>
<td align="center" valign="top">(n = 49)
</td>
</tr>
<tr>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top">%
</td>
<td class="Botrule" align="center" valign="top">%
</td>
<td class="Botrule" align="center" valign="top">%
</td>
<td class="Botrule" align="center" valign="top">%
</td>
</tr>
<tr>
<td align="left" valign="top">Body as a whole
</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span>
</td>
<td align="center" valign="top">5
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">12
</td>
<td align="center" valign="top">12
</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>
</td>
<td align="center" valign="top">1
</td>
<td align="center" valign="top">1
</td>
<td align="center" valign="top">1
</td>
<td align="center" valign="top">0
</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>
</td>
<td align="center" valign="top">2
</td>
<td align="center" valign="top">1
</td>
<td align="center" valign="top">1
</td>
<td align="center" valign="top">2
</td>
</tr>
<tr>
<td align="left" valign="top"> 
</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Gastrointestinal
</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>
</td>
<td align="center" valign="top">6
</td>
<td align="center" valign="top">1
</td>
<td align="center" valign="top">1
</td>
<td align="center" valign="top">2
</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>
</td>
<td align="center" valign="top">&lt;1
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">0
</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span>
</td>
<td align="center" valign="top">3
</td>
<td align="center" valign="top">1
</td>
<td align="center" valign="top">1
</td>
<td align="center" valign="top">0
</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span>
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">1
</td>
<td align="center" valign="top">2
</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>
</td>
<td align="center" valign="top">&lt;1
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">2
</td>
<td align="center" valign="top">0
</td>
</tr>
<tr>
<td align="left" valign="top">     Taste distortion
</td>
<td align="center" valign="top">1
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">0
</td>
</tr>
<tr>
<td align="left" valign="top"> 
</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Central and peripheral
</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">nervous systems
</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>
</td>
<td align="center" valign="top">11
</td>
<td align="center" valign="top">3
</td>
<td align="center" valign="top">4
</td>
<td align="center" valign="top">4
</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span>
</td>
<td align="center" valign="top">&lt;1
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">0
</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span>
</td>
<td align="center" valign="top">&lt;1
</td>
<td align="center" valign="top">2
</td>
<td align="center" valign="top">2
</td>
<td align="center" valign="top">2
</td>
</tr>
<tr>
<td align="left" valign="top"> 
</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Autonomic nervous
</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">system
</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">Nasal stuffiness</span>
</td>
<td align="center" valign="top">3
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">0
</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4088757" conceptname="Anejaculation">Ejaculation failure</span>
</td>
<td align="center" valign="top">2
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">0
</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Impotence</span>
</td>
<td align="center" valign="top">1
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">1
</td>
<td align="center" valign="top">3
</td>
</tr>
<tr>
<td align="left" valign="top">     Increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>
</td>
<td align="center" valign="top">&lt;1
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">0
</td>
</tr>
<tr>
<td align="left" valign="top"> 
</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Cardiovascular
</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span>
</td>
<td align="center" valign="top">1
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">0
</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Postural hypotension</span>
</td>
<td align="center" valign="top">1
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">0
</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">5
</td>
<td align="center" valign="top">12
</td>
</tr>
<tr>
<td align="left" valign="top"> 
</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Respiratory
</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span>
</td>
<td align="center" valign="top">2
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">1
</td>
<td align="center" valign="top">2
</td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Skin
</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>
</td>
<td align="center" valign="top">1
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">0
</td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Special senses
</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">     Vision abnormality
</td>
<td align="center" valign="top">1
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">0
</td>
</tr>
<tr class="Last">
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span>
</td>
<td align="center" valign="top">2
</td>
<td align="center" valign="top">1
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">0
</td>
</tr>
</tbody>
</table>
<p> The adverse effects were reported spontaneously and are representative of the incidence of adverse effects that may be observed in a properly selected hypertensive patient population, i.e., a group excluding patients with bronchospastic disease, overt <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, or other contraindications to beta-blocker therapy.
</p>
<p> Clinical trials also included studies utilizing daily doses up to 2,400 mg in more severely hypertensive patients. Certain of the side effects increased with increasing dose, as shown in the following table that depicts the entire US therapeutic trials data base for adverse reactions that are clearly or possibly dose related.
</p>
<table width="100%">
<col align="left" width="25.008%">
<col align="left" width="8.332%">
<col align="left" width="8.332%">
<col align="left" width="8.332%">
<col align="left" width="8.332%">
<col align="left" width="8.332%">
<col align="left" width="8.332%">
<col align="left" width="8.332%">
<col align="left" width="8.332%">
<col align="left" width="8.332%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="center" valign="bottom">Labetalol HCl<br>Daily Dose (mg)
</td>
<td class="Botrule Toprule" align="center" valign="bottom">200
</td>
<td class="Botrule Toprule" align="center" valign="bottom">300
</td>
<td class="Botrule Toprule" align="center" valign="bottom">400
</td>
<td class="Botrule Toprule" align="center" valign="bottom">600
</td>
<td class="Botrule Toprule" align="center" valign="bottom">800
</td>
<td class="Botrule Toprule" align="center" valign="bottom">900
</td>
<td class="Botrule Toprule" align="center" valign="bottom">1,200
</td>
<td class="Botrule Toprule" align="center" valign="bottom">1,600
</td>
<td class="Botrule Toprule" align="center" valign="bottom">2,400
</td>
</tr>
<tr>
<td align="left" valign="top">Number of patients
</td>
<td align="center" valign="top">522
</td>
<td align="center" valign="top">181
</td>
<td align="center" valign="top">606
</td>
<td align="center" valign="top">608
</td>
<td align="center" valign="top">503
</td>
<td align="center" valign="top">117
</td>
<td align="center" valign="top">411
</td>
<td align="center" valign="top">242
</td>
<td align="center" valign="top">175
</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> (%)
</td>
<td align="center" valign="top">2
</td>
<td align="center" valign="top">3
</td>
<td align="center" valign="top">3
</td>
<td align="center" valign="top">3
</td>
<td align="center" valign="top">5
</td>
<td align="center" valign="top">1
</td>
<td align="center" valign="top">9
</td>
<td align="center" valign="top">13
</td>
<td align="center" valign="top">16
</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span>
</td>
<td align="center" valign="top">2
</td>
<td align="center" valign="top">1
</td>
<td align="center" valign="top">4
</td>
<td align="center" valign="top">4
</td>
<td align="center" valign="top">5
</td>
<td align="center" valign="top">3
</td>
<td align="center" valign="top">7
</td>
<td align="center" valign="top">6
</td>
<td align="center" valign="top">10
</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>
</td>
<td align="center" valign="top">&lt;1
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">1
</td>
<td align="center" valign="top">2
</td>
<td align="center" valign="top">4
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">7
</td>
<td align="center" valign="top">11
</td>
<td align="center" valign="top">19
</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">&lt;1
</td>
<td align="center" valign="top">&lt;1
</td>
<td align="center" valign="top">&lt;1
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">1
</td>
<td align="center" valign="top">2
</td>
<td align="center" valign="top">3
</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span>
</td>
<td align="center" valign="top">1
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">2
</td>
<td align="center" valign="top">1
</td>
<td align="center" valign="top">1
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">2
</td>
<td align="center" valign="top">2
</td>
<td align="center" valign="top">4
</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span>
</td>
<td align="center" valign="top">2
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">2
</td>
<td align="center" valign="top">2
</td>
<td align="center" valign="top">1
</td>
<td align="center" valign="top">1
</td>
<td align="center" valign="top">2
</td>
<td align="center" valign="top">5
</td>
<td align="center" valign="top">5
</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">Nasal stuffiness</span>
</td>
<td align="center" valign="top">1
</td>
<td align="center" valign="top">1
</td>
<td align="center" valign="top">2
</td>
<td align="center" valign="top">2
</td>
<td align="center" valign="top">2
</td>
<td align="center" valign="top">2
</td>
<td align="center" valign="top">4
</td>
<td align="center" valign="top">5
</td>
<td align="center" valign="top">6
</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4088757" conceptname="Anejaculation">Ejaculation failure</span>
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">2
</td>
<td align="center" valign="top">1
</td>
<td align="center" valign="top">2
</td>
<td align="center" valign="top">3
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">4
</td>
<td align="center" valign="top">3
</td>
<td align="center" valign="top">5
</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Impotence</span>
</td>
<td align="center" valign="top">1
</td>
<td align="center" valign="top">1
</td>
<td align="center" valign="top">1
</td>
<td align="center" valign="top">1
</td>
<td align="center" valign="top">2
</td>
<td align="center" valign="top">4
</td>
<td align="center" valign="top">3
</td>
<td align="center" valign="top">4
</td>
<td align="center" valign="top">3
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span>
</td>
<td class="Botrule" align="center" valign="top">1
</td>
<td class="Botrule" align="center" valign="top">0
</td>
<td class="Botrule" align="center" valign="top">1
</td>
<td class="Botrule" align="center" valign="top">1
</td>
<td class="Botrule" align="center" valign="top">1
</td>
<td class="Botrule" align="center" valign="top">0
</td>
<td class="Botrule" align="center" valign="top">1
</td>
<td class="Botrule" align="center" valign="top">2
</td>
<td class="Botrule" align="center" valign="top">2
</td>
</tr>
</tbody>
</table>
<p> In addition, a number of other less common adverse events have been reported:
</p>
<p><span class="Bold Italics">Body as a Whole:</span> <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>.
</p>
<p><span class="Bold Italics">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, and rarely, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>.
</p>
<p><span class="Bold Italics">Central and Peripheral Nervous Systems:</span> <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span>, most frequently described as scalp <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>. In most cases, it was mild and transient and usually occurred at the beginning of treatment.
</p>
<p><span class="Bold Italics">Collagen Disorders:</span> <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">Systemic lupus erythematosus</span>, positive antinuclear factor.
</p>
<p><span class="Bold Italics">Eyes:</span> <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">Dry eyes</span>.
</p>
<p><span class="Bold Italics">Immunological System:</span> Antimitochondrial antibodies.
</p>
<p><span class="Bold Italics">Liver and Biliary System:</span> <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">Hepatic necrosis</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>, elevated liver function tests.
</p>
<p><span class="Bold Italics">Musculoskeletal System:</span> <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle cramps</span>, <span class="product-label-link" type="condition" conceptid="81286" conceptname="Toxic myopathy">toxic myopathy</span>.
</p>
<p><span class="Bold Italics">Respiratory System:</span> <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span>.
</p>
<p><span class="Bold Italics">Skin and Appendages:</span> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rashes</span> of various types, such as generalized maculopapular, lichenoid, urticarial, <span class="product-label-link" type="condition" conceptid="132703" conceptname="Lichen planus">bullous lichen planus</span>, psoriaform, and facial <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>; Peyronie's disease; reversible <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>.
</p>
<p><span class="Bold Italics">Urinary System:</span> <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">Difficulty in micturition</span>, including acute urinary <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">bladder retention</span>.
</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>:</span> Rare reports of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (e.g., <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>) and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>.
</p>
<p> Following approval for marketing in the United Kingdom, a monitored release survey involving approximately 6,800 patients was conducted for further safety and efficacy evaluation of this product. Results of this survey indicate that the type, severity, and incidence of adverse effects were comparable to those cited above.
</p>
<p><span class="Bold">Potential Adverse Effects:</span> In addition, other adverse effects not listed above have been reported with other beta-adrenergic blocking agents.
</p>
<p><span class="Bold Italics">Central Nervous System:</span> Reversible mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> progressing to <span class="product-label-link" type="condition" conceptid="4085823" conceptname="Catatonia">catatonia</span>, an acute reversible syndrome characterized by <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span> for time and place, short-term <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">memory loss</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, slightly clouded sensorium, and decreased performance on psychometrics.
</p>
<p><span class="Bold Italics">Cardiovascular:</span> Intensification of A-V block (see <a href="#s7">CONTRAINDICATIONS</a>).
</p>
<p><span class="Bold Italics">Allergic:</span> <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> combined with aching and <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>.
</p>
<p><span class="Bold Italics">Hematologic:</span> <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span>, thrombocytopenic or nonthrombocytopenic <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>.
</p>
<p><span class="Bold Italics">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="4348039" conceptname="Thrombosis of mesenteric artery">Mesenteric artery thrombosis</span>, <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span>.
</p>
<p> The <span class="product-label-link" type="condition" conceptid="4317263" conceptname="Ocular-mucous membrane syndrome">oculomucocutaneous syndrome</span> associated with the beta-blocker practolol has not been reported with labetalol HCl.
</p>
<p><span class="Bold">Clinical Laboratory Tests:</span> There have been reversible increases of serum transaminases in 4% of patients treated with labetalol HCl and tested and, more rarely, reversible increases in blood urea.
</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s33"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE
</h1>
<p class="First">Overdosage with labetalol HCl causes excessive <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> that is posture sensitive and, sometimes, excessive <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>. Patients should be placed supine and their legs raised if necessary to improve the blood supply to the brain. If overdosage with labetalol HCl follows oral ingestion, gastric lavage or pharmacologically induced <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> (using syrup of ipecac) may be useful for removal of the drug shortly after ingestion. The following additional measures should be employed if necessary: <span class="Bold">Excessive <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span></span>—administer atropine or epinephrine. <span class="Bold"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac failure</span></span>—administer a digitalis glycoside and a diuretic. Dopamine or dobutamine may also be useful. <span class="Bold"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></span>—administer vasopressors, e.g., norepinephrine. There is pharmacologic evidence that norepinephrine may be the drug of choice. <span class="Bold"><span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span></span>—administer epinephrine and/or an aerosolized beta<span class="Sub">2</span>-agonist. <span class="Bold"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></span>—administer diazepam.
</p>
<p> In severe beta-blocker <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> resulting in <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, glucagon has been shown to be effective when administered in large doses (5 to 10 mg rapidly over 30 seconds, followed by continuous infusion of 5 mg per hour that can be reduced as the patient improves).
</p>
<p> Neither hemodialysis nor peritoneal dialysis removes a significant amount of labetalol HCl from the general circulation (&lt;1%).
</p>
<p> The oral LD<span class="Sub">50</span> value of labetalol HCl in the mouse is approximately 600 mg/kg and in the rat is &gt;2 g/kg. The IV LD<span class="Sub">50</span> in these species is 50 to 60 mg/kg.
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s34"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION
</h1>
<p class="First">DOSAGE MUST BE INDIVIDUALIZED. The recommended <span class="Italics">initial</span> dosage is 100 mg <span class="Italics">twice</span> daily whether used alone or added to a diuretic regimen. After 2 or 3 days, using standing blood pressure as an indicator, dosage may be titrated in increments of 100 mg b.i.d. every 2 or 3 days. The usual <span class="Italics">maintenance</span> dosage of labetalol HCl is between 200 and 400 mg <span class="Italics">twice</span> daily.
</p>
<p> Since the full antihypertensive effect of labetalol HCl is usually seen within the first 1 to 3 hours of the initial dose or dose increment, the assurance of a lack of an exaggerated hypotensive response can be clinically established in the office setting. The antihypertensive effects of continued dosing can be measured at subsequent visits, approximately 12 hours after a dose, to determine whether further titration is necessary.
</p>
<p> Patients with severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> may require from 1,200 to 2,400 mg per day, with or without thiazide diuretics. Should side effects (principally <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>) occur with these doses administered twice daily, the same total daily dose administered three times daily may improve tolerability and facilitate further titration. Titration increments should not exceed 200 mg twice daily.
</p>
<p> When a diuretic is added, an additive antihypertensive effect can be expected. In some cases this may necessitate a labetalol HCl dosage adjustment. As with most antihypertensive drugs, optimal dosages of TRANDATE Tablets are usually lower in patients also receiving a diuretic.
</p>
<p> When transferring patients from other antihypertensive drugs, TRANDATE Tablets should be introduced as recommended and the dosage of the existing therapy progressively decreased.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s35"></a><a name="section-9.1"></a><p></p>
<p class="First"><span class="Bold">Elderly Patients:</span> As in the general patient population, labetalol therapy may be initiated at 100 mg twice daily and titrated upwards in increments of 100 mg b.i.d. as required for control of blood pressure. Since some elderly patients eliminate labetalol more slowly, however, adequate control of blood pressure may be achieved at a lower maintenance dosage compared to the general population. The majority of elderly patients will require between 100 and 200 mg b.i.d.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s36"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED
</h1>
<p class="First">TRANDATE Tablets, 100 mg, light orange, round, scored, film-coated tablets engraved on one side with "TRANDATE 100," bottles of 100 (NDC 65483-391-10) and 500 (NDC 65483-391-50) and unit dose packs of 100 tablets (NDC 65483-391-11).
</p>
<p> TRANDATE Tablets, 200 mg, white, round, scored, film-coated tablets engraved on one side with "TRANDATE 200," bottles of 100 (NDC 65483-392-10) and 500 (NDC 65483-392-50) and unit dose packs of 100 tablets (NDC 65483-392-22).
</p>
<p> TRANDATE Tablets, 300 mg, mid-orange, round, scored, film-coated tablets engraved on one side with "TRANDATE 300," bottles of 100 (NDC 65483-393-10) and 500 (NDC 65483-393-50) and unit dose packs of 100 tablets (NDC 65483-393-33).
</p>
<p><span class="Bold">TRANDATE Tablets should be stored between 2° and 30°C (36° and 86°F). TRANDATE Tablets in the unit dose boxes should be protected from excessive moisture.</span></p>
<p>Prometheus Laboratories Inc.<br>Manufactured in Canada by WellSpring Pharmaceutical Canada Corp.<br>Oakville, ON L6H 1M5<br>for Prometheus Laboratories Inc.<br>San Diego, CA 92121
</p>
<p>
TRANDATE is a registered trademark of Prometheus Laboratories, Inc.</p>
<p>
TOXI-LAB is a registered trademark of Varian, Inc.</p>
<p>
EMIT and EMIT-d.a.u. are registered trademarks of Siemens Healthcare Diagnostics, Inc.
</p>
<p>© 2010 Prometheus Laboratories Inc.<br>All rights reserved<br>November 2010
</p>
<p>TR002C
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="j2"></a><a name="section-11"></a><p></p>
<h1>Principle Display Panel - 100 mg 100ct Bottle Label
</h1>
<p class="First">NDC 65483-391-10
</p>
<p>Prometheus Laboratories
</p>
<p>Trandate
</p>
<p>(labetalol hydrochloride)
</p>
<p>100 mg
</p>
<p>Each tablet
</p>
<p>contains labetalol
</p>
<p>hydrochloride
</p>
<p>100 mg
</p>
<p>Rx only
</p>
<p>100 Tablets
</p>
<div class="Figure">
<a name="f02"></a><img alt="100 mg 100ct Bottle Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a4195473-51a9-40f1-8678-1478ebca2d84&amp;name=tra08-0004-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="j3"></a><a name="section-12"></a><p></p>
<h1>Principle Display Panel - 200 mg 100ct Bottle Label
</h1>
<p class="First">NDC 65483-392-10
</p>
<p>Prometheus Laboratories
</p>
<p>Trandate
</p>
<p>(labetalol hydrochloride)
</p>
<p>200 mg
</p>
<p>Each tablet
</p>
<p>contains labetalol
</p>
<p>hydrochloride
</p>
<p>200 mg
</p>
<p>Rx only
</p>
<p>100 Tablets
</p>
<div class="Figure">
<a name="f03"></a><img alt="200 mg 100ct Bottle Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a4195473-51a9-40f1-8678-1478ebca2d84&amp;name=tra08-0004-03.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="j4"></a><a name="section-13"></a><p></p>
<h1>Principle Display Panel - 300 mg 100ct Bottle Label
</h1>
<p class="First">NDC 65483-393-10
</p>
<p>Prometheus Laboratories
</p>
<p>Trandate
</p>
<p>(labetalol hydrochloride)
</p>
<p>300 mg
</p>
<p>Each tablet
</p>
<p>contains labetalol
</p>
<p>hydrochloride
</p>
<p>300 mg
</p>
<p>Rx only
</p>
<p>100 Tablets
</p>
<div class="Figure">
<a name="f04"></a><img alt="300 mg 100ct Bottle Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a4195473-51a9-40f1-8678-1478ebca2d84&amp;name=tra08-0004-04.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TRANDATE 		
					</strong><br><span class="contentTableReg">labetalol hydrochloride tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:65483-391</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>labetalol hydrochloride</strong> (labetalol) </td>
<td class="formItem">labetalol hydrochloride</td>
<td class="formItem">100 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C Yellow No. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hypromellose 2208 (15000 mpa.s)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>starch, corn</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>talc</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">orange (orange) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (ROUND) </td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">TRANDATE;100
</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:65483-391-10</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA018716</td>
<td class="formItem">05/31/1984</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TRANDATE 		
					</strong><br><span class="contentTableReg">labetalol hydrochloride tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:65483-392</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>labetalol hydrochloride</strong> (labetalol) </td>
<td class="formItem">labetalol hydrochloride</td>
<td class="formItem">200 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hypromellose 2208 (15000 mpa.s)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>lactose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>starch, corn</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (white) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (ROUND) </td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">TRANDATE;200
</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:65483-392-10</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA018716</td>
<td class="formItem">05/31/1984</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TRANDATE 		
					</strong><br><span class="contentTableReg">labetalol hydrochloride tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:65483-393</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>labetalol hydrochloride</strong> (labetalol) </td>
<td class="formItem">labetalol hydrochloride</td>
<td class="formItem">300 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C Yellow No. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hypromellose 2208 (15000 mpa.s)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>starch, corn</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">orange (orange) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (ROUND) </td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">TRANDATE;300
</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:65483-393-10</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA018716</td>
<td class="formItem">05/31/1984</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Prometheus Laboratories Inc.
							(967000860)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">WellSpring Pharmaceutical Canada Corp.</td>
<td class="formItem"></td>
<td class="formItem">251086799</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>8d2825c1-c676-4a48-bb9f-e0e2b7cc9ee1</div>
<div>Set id: a4195473-51a9-40f1-8678-1478ebca2d84</div>
<div>Version: 4</div>
<div>Effective Time: 20091214</div>
</div>
</div> <div class="DistributorName">Prometheus Laboratories Inc.</div></p>
</body></html>
